Ensign Peak Advisors, Inc Codiak Bio Sciences, Inc. Transaction History

Ensign Peak Advisors, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.32 - $0.9 $85,612 - $240,785	-267,539 Reduced 51.42%	252,782 $101,000
Q3 2022 Nov 14, 2022	SELL	$0.82 - $3.19 $72,802 - $283,220	-88,784 Reduced 14.58%	520,321 $407,000
Q2 2022 Aug 12, 2022	SELL	$2.24 - $6.96 $133,017 - $413,305	-59,383 Reduced 8.88%	609,105 $1.75 Million
Q1 2022 May 16, 2022	BUY	$4.3 - $12.95 $683,919 - $2.06 Million	159,051 Added 31.22%	668,488 $4.19 Million
Q4 2021 Feb 11, 2022	BUY	$10.0 - $16.78 $354,300 - $594,515	35,430 Added 7.47%	509,437 $5.68 Million
Q3 2021 Nov 12, 2021	SELL	$15.58 - $22.88 $2.75 Million - $4.04 Million	-176,505 Reduced 27.13%	474,007 $7.74 Million
Q1 2021 May 12, 2021	SELL	$13.49 - $31.53 $2.28 Million - $5.34 Million	-169,315 Reduced 20.65%	650,512 $9.81 Million
Q4 2020 Feb 12, 2021	BUY	$7.9 - $32.3 $6.48 Million - $26.5 Million	819,827 New	819,827 $26.5 Million

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.